Creatine and phosphocreatine: A review of their use in exercise and sport

Journal of Athletic Training

Volumn 32, Issue 1, 1997, Pages 45-51

  Clark, Joseph F ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ADP; Anaerobic exercise; ATP; Creatine kinase; Energy metabolism; Muscle

Indexed keywords

EID: 0001936176     PISSN: 10626050     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Agnese L, Tarello M, Grazioli I. Efficacia della creatina fosfato nel trattamento della ipotonotrofia da non uso della muscolatura scheletrica. Ort e Traum Oggi. 1992;12:107-113.
2. Balsom PD, Ekblom B, Soderlund K, Sjodin B, Hultman E. Creatine supplementation and dynamic high-intensity intermittent exercise. Scand J Med Sci Sports. 1993;3:143-149.
3. Birch R, Novel D, Greenhaff PL. The influence of dietary creatine supplementation on performance during repeated bouts of maximal isokinetic cycling in man. Eur J Appl Physiol. 1994;69:268-270.
4. Casey A, Constantin-Teodosiu D, Howell S, Hultman E, Greenhaff PL. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Am J Physiol. 1996;271:E31-E37.
5. Casey A, Constantin-Teodosiu D, Howell S, Hultman E, Greenhaff PL. Metabolic response of type I and II muscle fibers during repeated bouts of maximal exercise in humans. Am J Physiol. 1996;271:E38-E43.
6. Clark JF. Uses of creatine phosphate and creatine supplementation for the athlete. In: Conway MA, Clark JF, eds. Creatine and Creatine Phosphate: Scientific and Clinical Perspectives. London: Academic Press; 1996:217-225.
7. Dal Monte A, Leonardi LM, Figura F, Cappozzo A, Marchetti M, De Sanctis AM, Nofroni I. Effetti dell'apporto esogeno di fosfocreatina sulla potenza muscolare umana. Gazz. Med. Ital. 1976;135:2-11.
8. Gelfgan EB, Dalili IG, Shakhtakhtinskaya FN, Yagisarova NM, Shirinova EA. The effect of phosphocreatine on the tolerance of physical exercise in patients with ischemic heart disease. In: Saks VA, Bobkov YG, Strumia E, eds. Creatine Phosphate: Biochemistry, Pharmacology, and Clinical Efficiency. Torino Italy: Edizioni Minerva Medica; 1987:270.
9. Green AL, Hultman E, Macdonald IA, Sewell DA, Greenhaff PL. Carbohydrate ingestion augments skeletal muscle creatine accumulation during creatine supplementation in man. Am J Physiol. 1996;271:E821-E826.
10. Greenhaff PL, Bodin K, Soderlund K, Hultman E. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am J Physiol. 1994;266:E725-E730.
11. Pirola V, Pisani L, Teruzzi P. Valutazione del recupero del trofismo muscolare in pazienti anziani con frattura di femore trattati con creatina fosfato e fisokinesiterapia. Clin. Ter. 1991;139:115-119.
12. Tegazzin V, Rossi M, Schiavon M, Schiavon R, Bettini V, Aragno R, Bitozzi A. Indagine sulla performance di ciclisti trattati e non trattati con fosfocreatina. Biol Med. 1991;13:121-135.
13. Walker JB. Bioenergetic engineering with guanidino compounds: loading tissues with extended-range synthetic thermodynamic buffers. In: De Deyn PP, Marescau B, Stalon V, Qureshi IA, eds. Guanidino Compounds in Biology and Medicine. London: John Libbey and Co.; 1992:187-194.
14. Sipila I, Rapola J, Simell O, Vannas A. Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. N. Engl. J. Med. 1981;304:867-870.
15. Stockler S, Hanefeld F, Frahm J. Creatine replacement therapy in guanidinoacetate methyltransferase deficiency: a novel inborn error of metabolism. Lancet. 1996;348:789-790.
16. Sanford L, Tikunov B, Henson D, Lamanca J, Sweeney HL. Creatine depletion elicits structural, biochemical, and physiological adaptations in the rat costal diaphragm. Am J Physiol. 1996;40:C1480-C1486.
17. Conway MA, Ouwerkerk R, Rajagopalan B, Radda GK. Creatine phosphate: in vivo human cardiac metabolism studied by magnetic resonance spectroscopy. In: Conway MA, Clark JF, eds. Creatine and Creatine Phosphate: Scientific and Clinical Perspectives. London: Academic Press; 1996:127-160.
18. Trump ME, Heigenhauser GJF, Putman CT, Spriet LL. Importance of muscle phosphocreatine during intermittent maximal cycling. J Appl Physiol. 1996;80:1574-1580.
19. Wallimann T, Wyss M, Brdczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation structure and function of creatine kinase isozymes in tissue with high and fluctuating energy demands: the phosphocreatine circuit for cellular energy homeostasis. Biochem J. 1992;1102:21-40.
20. Greenhaff PL, Bodin K, Harris RC, Hultman E, Jones DA, McIntyre DB, Soderlund K, Turner DL. The influence of oral creatine supplementation on muscle phosphocreatine resynthesis following intense contraction in man. J Physiol. 1993;467:75P.
21. Harris RC, Soderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci. 1992;83:367-374.
22. Balsom PD, Harridge SDR, Soderlund K, Sjodin B, Ekblom B. Creatine supplementation per se does not' enhance endurance performance. Acta Physiol Scand. 1993;149:521-523.
23. Bloch K, Schoenheimer R, Rittenberg D. Rate of formation and disappearance of body creatine in normal animals. J Biol Chem. 1941;138:155-166.
24. Earnest CP, Snell PG, Rodriguez R, Almada AL, Mitchell TL. The effect of creatine monohydrate ingestion on anaerobic power indices, muscular strength, and body composition. Acta Physiol Scand. 1995;153:207-209.
25. Moller A, Hamprecht B. Creatine transport in cultured cells of rat and mouse brain. J Neurochem. 1989;52:544-550.
26. Walker JB. Creatine: biosynthesis, regulation, and function. In: Meister A, ed. Advances in Enzymology. Vol 50. New York: John Wiley and Sons; 1979:177-242.
27. Harris RC, Viru M, Greenhaff PL, Hultman E. The effect of oral creatine supplementation on running performance during maximal short term exercise in man. J Physiol. 1993;467:74P.
28. Greenhaff PL, Casey A, Short AH, Harris R, Soderlund K, Hultman E. Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. Clin. Sci. 1993;84: 565-571.
29. Hultman E, Soderlund K, Timmons JA, Cederblad G, Greenhaff PL. Muscle creatine loading in man. J Appl Physiol. 1996;81:232-237.
30. Bessman SP, Mohan C. Phosphocreatine, exercise, protein synthesis, and insulin. In: De Deyn PP, Marescau B, Stalon V, Qureshi IA, eds. Guanidino Compounds in Biology and Medicine. London: John Libbey and Co.; 1992:181-186.
31. Fitch CD, Shields RP. Creatine metabolism in skeletal muscle. I. Creatine movement across muscle membranes. J Biol Chem. 1966;241:3611-3614.
32. Carpenter CL, Mohan C, Bessman SP. Inhibition of protein and lipid synthesis in muscle by 2:4-dinitrofluorobenzene, an inhibitor of creatine phosphokinase. Biochem Biophys Res Comm. 1983;111:884-889.
33. Earnest CP, Almada AL, Mitchell TL. High performance capillary electrophoresis-pure creatine monohydrate reduces blood lipids in men and women. Clin. Sci. 1996;91:113-118.
34. Clark JF, Odoom J, Tracey I, Dunn J, Boehm EA, Paternostro G, Radda GK. Experimental observations of creatine and creatine phosphate metabolism. In: Conway MA, Clark JF, eds. Creatine and Creatine Phosphate: Scientific and Clinical Perspectives. London: Academic Press; 1996:33-50.
35. Rose WC. The metabolism of creatine and creatinine. Ann Rev Biochem. 1933;2:187-206.
36. Scott DP, Davidheiser S, Coburn RF. Effects of elevation of phosphocreatine on force and metabolism in rabbit aorta. Am J Physiol. 1987;253: H461-H465.
37. Saks VA, Javadov SA, Pozin E, Preobrazhensky AN. Biochemical basis of the protective action of phosphocreatine on the ischemic myocardium. In: Saks VA, Bobkov YG, Strumia E, eds. Creatine Phosphate: Biochemistry, Pharmacology, and Clinical Efficiency. Torino Italy: Edizioni Minerva Medica; 1987:270-273.
38. Saks' VA, Kuznetsov AV, Kupriyanov VV, Miceli MV, Jacobus WE. Creatine kinase of rat heart mitochondria. J Biol Chem. 1985;891:138-144.
39. Saks VA, Strumia E. Phosphocreatine: molecular and cellular aspects of the mechanism of cardioprotective action. Curr Ther Res. 1993;53:565-598.
40. Sharov VG, Saks VA, Kupriyanov VV, Lakomkin VL, Kapelko VI, Steinschneider AY, Javadov SA. Protection of ischemic myocardium by exogenous phosphocreatine I. Morphologic and phosphorus 31-Nuclear magnetic resonance studies. J Thorac Cardiovasc Surg. 1987;94:749-761.
41. Satolli F, Marchesi G. Creatine phosphate in rehabilitation of patients with muscles hypotonotrophy of the lower extremity. Curr Ther Res. 1989;46: 67-73.
42. Piacenza G, Strumia E, Lorenzi E, Borgoglio R. Creatine phosphate effects on red blood cells. In: Saks VA, Bobkov YG, Strumia E, eds. Creatine Phosphate: Biochemistry, Pharmacology, and Clinical Efficiency. Torino Italy: Edizioni Minerva Medica; 1987:177-184.
43. Down WH, Chasseaud LF, Ballard SA. The effect of intravenously administered phosphocreatine on ATP and phosphocreatine concentrations in the cardiac muscle of the rat. Arzneim Forsh. 1983;33:552-554.
44. Fagbemi O, Kane KA, Parratt JR. Creatine phosphate suppresses ventricular arrhythmias resulting from coronary artery ligation. J Cardiovasc Pharmacol. 1982;4:53-58.
45. Conway MA, Rajagopalan B, Radda GK. Skeletal muscle metabolism in heart failure. In: Conway MA, Clark JF, eds. Creatine and Creatine Phosphate: Scientific and Clinical Perspectives. London: Academic Press; 1996:161-184.